Macquarie Group
BCRX icon

Macquarie Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Macquarie Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-249,495
Closed -$1.9M – 1669
2024
Q3 		$1.9M Buy
+249,495
New +$1.9M ﹤0.01% 1245
2022
Q4 		– Sell
-5,019
Closed -$80K – 1787
2022
Q3 		$80K Sell
5,019
-1,302
-21% -$16.8K ﹤0.01% 1825
2022
Q2 		$67K Hold
6,321
– – ﹤0.01% 1976
2022
Q1 		$103 Sell
6,321
-1,984
-24% -$31.8K ﹤0.01% 1941
2021
Q4 		$115K Buy
8,305
+1,803
+28% +$23.9K ﹤0.01% 1892
2021
Q3 		$93K Sell
6,502
-2,103
-24% -$33.2K ﹤0.01% 2006
2021
Q2 		$136K Buy
8,605
+253
+3% +$3.44K ﹤0.01% 1880
2021
Q1 		$85K Sell
8,352
-1,580
-16% -$16.3K ﹤0.01% 1955
2020
Q4 		$74K Hold
9,932
– – ﹤0.01% 1941
2020
Q3 		$34K Buy
9,932
+3,200
+48% +$13.7K ﹤0.01% 2033
2020
Q2 		$32K Buy
+6,732
New +$26.9K ﹤0.01% 2033
2018
Q1 		– Sell
-1,800
Closed -$9K – 2186
2017
Q4 		$9K Buy
+1,800
New +$8.72K ﹤0.01% 2271
2016
Q2 		– Sell
-25,529
Closed -$72K – 1570
2016
Q1 		$72K Sell
25,529
-113,719
-82% -$504K ﹤0.01% 1457
2015
Q4 		$1.44M Buy
139,248
+1,806
+1% +$18K ﹤0.01% 1009
2015
Q3 		$1.57M Buy
137,442
+23,807
+21% +$318K ﹤0.01% 1033
2015
Q2 		$1.7M Buy
113,635
+3,243
+3% +$36.9K ﹤0.01% 1067
2015
Q1 		$997K Sell
110,392
-31,775
-22% -$329K ﹤0.01% 1155
2014
Q4 		$1.73M Buy
142,167
+43,616
+44% +$482K ﹤0.01% 1058
2014
Q3 		$964K Buy
98,551
+64,451
+189% +$790K ﹤0.01% 1170
2014
Q2 		$435K Buy
+34,100
New +$332K ﹤0.01% 1335

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Macquarie Group's BCRX Position: Q4 2024 in Review

Macquarie Group sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 249,495 shares — an estimated $1.9M sold.

Macquarie Group first reported a position in BCRX in Q2 2014 and held it in 20 quarters. The position peaked at $1.9M in Q3 2024. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • Macquarie Group reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Macquarie Group sold 249,495 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $1.9M.
  • Macquarie Group first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 20 quarters.
  • Macquarie Group's BioCryst Pharmaceuticals position peaked at $1.9M in Q3 2024.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Macquarie Group's 13F filing for Q4 2024, filed 14 Feb 2025.